Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -2.22% 22.00 21.50 22.50 22.25 21.50 22.00 1,005,667 14:17:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.7 -0.3 - 14

ValiRx PLC Total Voting Rights

01/09/2020 7:00am

UK Regulatory (RNS & others)

Valirx (LSE:VAL)
Historical Stock Chart

From Aug 2020 to Oct 2020

Click Here for more Valirx Charts.


RNS Number : 4915X

ValiRx PLC

01 September 2020


("ValiRx", the "Company" or the "Group")

Total Voting Rights

London, UK 1 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company today updated its total voting rights disclosure position.

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, the total number of Ordinary Shares in issue will be 56,854,039. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 56,854,039 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As announced on 28 August 2020, application has been made to the London Stock Exchange to admit the 250,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 3 September 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.

Following admission of the 250,000 new ordinary shares to trading on AIM on or around 3 September 2020, the Company's total issued share capital will comprise 57,104,039 ordinary shares of 0.1 pence each.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

 ValiRx plc                                           Tel: +44 (0) 20 7073 
  Suzanne Dilly                           
   Cairn Financial Advisers LLP (Nominated             Tel: +44 (0) 20 7213 
   Adviser)                                                            0880 
   Liam Murray / Jo Turner / Ludovico Lazzaretti 
   Peterhouse Capital Limited (Sole Broker)            Tel: +44 (0) 20 7469 
   Duncan Vasey / Lucy Williams / Eran Zucker                          0930 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

September 01, 2020 02:00 ET (06:00 GMT)

1 Year Valirx Chart

1 Year Valirx Chart

1 Month Valirx Chart

1 Month Valirx Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201031 20:32:41